ALT – Altimmune Inc
Name : Altimmune, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.00000000000000
EPSttm :
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ALT
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ALT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
20.49
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
EPS Last/This Y
0.26
EPS This/Next Y
-0.16
Price
2.64
Target Price
16.06
Analyst Recom
1.5
Performance Q
-31.09
Upside
-559.4%
Beta
0.27
Ticker: ALT
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | ALT | 3.09 | 0.08 | 0.05 | 146841 |
| 2026-05-12 | ALT | 3.08 | 0.08 | 0.14 | 148050 |
| 2026-05-13 | ALT | 3.02 | 0.08 | 0.10 | 149455 |
| 2026-05-14 | ALT | 2.91 | 0.08 | 0.03 | 151178 |
| 2026-05-15 | ALT | 2.86 | 0.08 | 0.34 | 150144 |
| 2026-05-18 | ALT | 2.81 | 0.07 | 0.06 | 140853 |
| 2026-05-19 | ALT | 2.73 | 0.07 | 0.07 | 143195 |
| 2026-05-20 | ALT | 2.83 | 0.07 | 0.19 | 144183 |
| 2026-05-21 | ALT | 2.93 | 0.07 | 0.14 | 145215 |
| 2026-05-22 | ALT | 2.9 | 0.07 | 0.07 | 146356 |
| 2026-05-26 | ALT | 2.93 | 0.07 | 0.22 | 146793 |
| 2026-05-27 | ALT | 2.98 | 0.07 | 0.05 | 148996 |
| 2026-05-28 | ALT | 3.06 | 0.07 | 0.05 | 152997 |
| 2026-05-29 | ALT | 3.06 | 0.07 | 0.08 | 155415 |
| 2026-06-02 | ALT | 2.9 | 0.07 | 0.21 | 156394 |
| 2026-06-03 | ALT | 2.87 | 0.07 | 0.11 | 156848 |
| 2026-06-04 | ALT | 2.92 | 0.07 | 0.43 | 158528 |
| 2026-06-05 | ALT | 2.7 | 0.07 | 0.46 | 158206 |
| 2026-06-08 | ALT | 2.73 | 0.07 | 0.06 | 151953 |
| 2026-06-09 | ALT | 2.64 | 0.07 | 0.04 | 153912 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | ALT | 3.09 | 3.9 | -250.7 | -1.11 |
| 2026-05-12 | ALT | 3.07 | 3.9 | -249.8 | -1.11 |
| 2026-05-13 | ALT | 3.01 | 3.9 | -238.8 | -1.11 |
| 2026-05-14 | ALT | 2.91 | 3.9 | -222.1 | -1.11 |
| 2026-05-15 | ALT | 2.86 | 3.9 | - | -1.11 |
| 2026-05-18 | ALT | 2.81 | 7.9 | - | -1.11 |
| 2026-05-19 | ALT | 2.74 | 7.9 | - | -1.11 |
| 2026-05-20 | ALT | 2.83 | 7.9 | - | -0.76 |
| 2026-05-21 | ALT | 2.93 | 7.9 | - | -0.74 |
| 2026-05-22 | ALT | 2.90 | 40.7 | - | -0.74 |
| 2026-05-26 | ALT | 2.93 | 40.7 | - | -0.74 |
| 2026-05-27 | ALT | 2.99 | 40.7 | - | -0.74 |
| 2026-05-28 | ALT | 3.06 | 40.7 | - | -0.74 |
| 2026-05-29 | ALT | 3.06 | 40.7 | - | -0.74 |
| 2026-06-01 | ALT | 3.01 | 40.7 | - | -0.74 |
| 2026-06-02 | ALT | 2.90 | 40.7 | - | -0.74 |
| 2026-06-03 | ALT | 2.87 | 40.7 | - | -0.74 |
| 2026-06-04 | ALT | 2.92 | 40.7 | - | -0.74 |
| 2026-06-05 | ALT | 2.70 | 40.7 | - | -0.74 |
| 2026-06-08 | ALT | 2.74 | 40.7 | - | -0.74 |
| 2026-06-09 | ALT | 2.64 | 40.7 | - | -0.74 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | ALT | 8.09 | 20.60 | 16.12 |
| 2026-05-12 | ALT | 0.56 | 20.60 | 19.89 |
| 2026-05-13 | ALT | 0.56 | 20.60 | 19.89 |
| 2026-05-14 | ALT | 0.56 | 20.60 | 19.89 |
| 2026-05-15 | ALT | 0.56 | 20.60 | 19.89 |
| 2026-05-18 | ALT | 0.56 | 19.55 | 19.30 |
| 2026-05-19 | ALT | 0.84 | 19.55 | 19.30 |
| 2026-05-20 | ALT | 0.84 | 19.55 | 19.30 |
| 2026-05-21 | ALT | 0.84 | 19.55 | 19.30 |
| 2026-05-22 | ALT | 0.84 | 19.55 | 19.30 |
| 2026-05-26 | ALT | 0.84 | 16.78 | 19.30 |
| 2026-05-27 | ALT | 0.84 | 16.78 | 19.30 |
| 2026-05-28 | ALT | 0.84 | 16.78 | 20.49 |
| 2026-05-29 | ALT | 0.84 | 16.78 | 20.49 |
| 2026-06-02 | ALT | 0.84 | 16.26 | 20.49 |
| 2026-06-03 | ALT | 0.84 | 16.26 | 20.49 |
| 2026-06-04 | ALT | 0.84 | 16.26 | 20.49 |
| 2026-06-05 | ALT | 0.84 | 16.26 | 20.49 |
| 2026-06-08 | ALT | 0.84 | 16.26 | 20.49 |
| 2026-06-09 | ALT | 0.84 | 16.26 | 20.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ALT
589 360 ]
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
0.84
Institutional Transactions
16.26
Beta
0.27
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
29
Growth Score
23
Sentiment Score
2
Actual DrawDown %
88.8
Max Drawdown 5-Year %
-90.5
Target Price
16.06
P/E
Forward P/E
PEG
P/S
12932.26
P/B
1.22
P/Free Cash Flow
EPS
-0.94
Average EPS Est. Cur. Y
-0.74
EPS Next Y. (Est.)
-0.9
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-253002.78
Relative Volume
0.87
Return on Equity vs Sector %
-59.6
Return on Equity vs Industry %
-43.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.74
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ALT
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ALT
589 450 ]
◆
ALT
Healthcare
$2.66
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
15/25
Volume
7/15
Valuation
12/20
TP/AR
2/10
Options
8/10
RSI
36.4
Range 1M
4.2%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
7/25
Growth
17/30
Estimates
0/20
Inst/Vol
5/15
Options
8/10
EPS Yr
30.9%
EPS NY
-11.1%
52W%
1.6%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+503.8% upside
Quality
2/30
Valuation
16/30
Growth
12/25
Stability
7/10
LT Trend
4/5
Upside
+503.8%
Quality
29
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 57
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
[News_ALT
_Stock]
stock quote shares ALT – Altimmune Inc Stock Price stock today
news today ALT – Altimmune Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALT – Altimmune Inc yahoo finance google finance
stock history ALT – Altimmune Inc invest stock market
stock prices ALT
premarket after hours
ticker ALT
fair value insiders trading